Insulin isophane human - Biologic Drug Details

Summary for insulin isophane human

Tradenames:	2
High Confidence Patents:	2
Applicants:	2
BLAs:	4
Suppliers: see list	3

Pharmacology for insulin isophane human

Established Pharmacologic Class	Insulin
Chemical Structure	Insulin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for insulin isophane human Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for insulin isophane human Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	NOVOLIN 70/30	insulin isophane human and insulin human	Injection	019991	4,973,318	2009-02-09	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOLIN 70/30	insulin isophane human and insulin human	Injection	019991	5,462,535	2014-10-14	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for insulin isophane human Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	HUMULIN N	insulin isophane human	Injectable Suspension	018781	10,660,941	2037-02-17	Patent claims search
Novo Nordisk Inc.	NOVOLIN N	insulin isophane human	Injectable Suspension	019959	10,660,941	2037-02-17	Patent claims search
Eli Lilly And Company	HUMULIN 70/30	insulin isophane human and insulin human	Injectable Suspension	019717	10,660,941	2037-02-17	Patent claims search
Novo Nordisk Inc.	NOVOLIN 70/30	insulin isophane human and insulin human	Injection	019991	10,016,338	2036-12-20	Patent claims search
Novo Nordisk Inc.	NOVOLIN 70/30	insulin isophane human and insulin human	Injection	019991	10,577,154	2038-12-19	Patent claims search
Novo Nordisk Inc.	NOVOLIN 70/30	insulin isophane human and insulin human	Injection	019991	10,660,941	2037-02-17	Patent claims search
Novo Nordisk Inc.	NOVOLIN 70/30	insulin isophane human and insulin human	Injection	019991	10,912,714	2038-07-09	Patent claims search

Insulin isophane human Market Analysis and Financial Projection

Last updated: February 15, 2026

What Are the Current Market Dynamics for Insulin Isophane Human?

The insulin isophane human market is characterized by sustained demand driven by the global diabetes prevalence. Insulin remains the primary therapy for type 1 diabetes and the second-line treatment for type 2 diabetes. The market is dominated by a few key players, including Novo Nordisk, Eli Lilly, Sanofi, and emerging biosimilar manufacturers.

Market Size and Growth

In 2022, the global insulin market was valued at approximately $27 billion, with insulin isophane human accounting for around 35% of sales, translating to roughly $9.45 billion. The compound annual growth rate (CAGR) from 2017 to 2022 has been approximately 4%. Projected growth estimates suggest a CAGR of 3-4% through 2028, aligned with the slow but steady increase in diabetes prevalence.

Drivers and Restraints

• Drivers:
  • Increasing prevalence of diabetes worldwide.
  • Growing awareness and diagnosis rates.
  • Continued utilization of biosimilars to reduce costs.
• Restraints:
  • Competition from insulin analogs with improved pharmacokinetics.
  • Penetration of newer delivery devices.
  • Pricing pressures and reimbursement challenges.

Market Share and Competitive Landscape

Company	Market Share (2022)	Key Products	Strategic Moves
Novo Nordisk	50%	Novolin N, Humulin N (biosimilars)	Expanding biosimilar portfolio
Eli Lilly	20%	Basaglar, Humalog (analog, not isophane)	Focus on biosimilar insulin
Sanofi	15%	Lantus (analog), Insuman (biosimilar)	Biosimilar entry planned
Others	15%	Various regional products	Mergers and collaborations

How Is the Financial Trajectory Shaping Up?

Revenue Trends and Profitability

The insulin isophane human segment exhibits stable revenue streams primarily due to patent expirations of branded biologics and the advent of biosimilars.

• Biosimilar insulins, predominantly from Novo Nordisk and Eli Lilly, entered markets between 2017 and 2020, leading to increased competition.
• Average selling prices (ASP) for insulin isophane human declined by an estimated 10% annually post-biosimilar entry.

Cost Dynamics

Manufacturing costs for insulin biosimilars are decreasing as production processes mature, leading to higher profit margins for manufacturers adopting efficient biomanufacturing. R&D expenses focus increasingly on biosimilar development, which is less costly than novel biologics.

Market Expansion and Emerging Opportunities

• Emerging Markets: India, Brazil, and Southeast Asia show high growth potential due to rising diabetes rates and lower per capita income, driving demand for affordable insulin.
• Digital and Delivery Innovation: Pen-based delivery systems and smart insulin pens improve adherence, presenting indirect revenue growth opportunities.

Financial Risks and Challenges

• Pricing pressures lead to margin compression.
• Regulatory pathways for biosimilars vary across regions, complicating market entry.
• Potential for market saturation as biosimperials proliferate.

How Do Market and Financial Trends Compare to Other Insulin Types?

Insulin Type	Market Share (2022)	Typical Price (per unit, USD)	Growth Rate (2017-2022)
Isophane Human	35%	$0.05-0.10	3-4%
Analogs (e.g., Lispro, Aspart)	50%	$0.20-0.50	7-8%
Pre-mixed insulins	15%	$0.10-0.30	2-3%

Insulin analogs have gained market share owing to their superior pharmacodynamics but are priced higher, constraining the price-sensitive segments in emerging markets.

What Are the Key Regulatory and Policy Trends?

• Approval pathways for biosimilar insulins vary; the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) require robust comparability data.
• There's increasing pressure on payers to negotiate discounts for biosimilars, affecting revenue projections.
• Patent expirations for key brands (e.g., Eli Lilly’s Humulin line and Sanofi’s Insuman) have opened markets for biosimilars, encouraging new entrants.

Regulatory Status (2023)

• Multiple biosimilar insulins, including insulin isophane human, are approved or under review in major markets.
• The U.S. has approved several biosimilars, with a pathway established in 2015 that eases approvals.

Summary of Market and Financial Outlook

The market for insulin isophane human remains stable but faces moderate compression. The shift toward biosimilars has driven cost reductions and increased market accessibility, especially in emerging economies. While traditional players maintain significant share through their existing portfolios, new entrants leveraging biosimilar manufacturing efficiencies and regional market strategies are gaining ground.

Profitability depends on manufacturing scale, patent landscapes, and regulatory agility. Opportunities exist in expanding into underserved markets and integrating digital health solutions for better patient engagement.

---

Key Takeaways

• The insulin isophane human market was valued at ~$9.45 billion in 2022.
• CAGR is approximately 3-4% through 2028, with biosimilars driving price competition.
• Leading companies are Novo Nordisk, Eli Lilly, and Sanofi, holding substantial market shares.
• Pricing pressures and regional regulatory variations influence revenue stability.
• Emerging markets and digital health tools present growth opportunities.

---

5 FAQs

1. What is the main driver for insulin isophane human market growth?
The primary driver is the increasing prevalence of diabetes globally, especially in emerging markets.

2. How is biosimilar insulin affecting the market?
Biosimilars reduce prices, increase market competition, and expand access but put downward pressure on revenues of originator companies.

3. Which regions offer the greatest growth potential?
Emerging markets such as India, Brazil, and Southeast Asia offer significant opportunities due to rising diabetes rates and affordability needs.

4. Are regulatory barriers a concern for new market entrants?
Yes, approval processes vary by region and require comprehensive comparability data, impacting time-to-market and costs.

5. How does the profitability of insulin isophane human compare to analogs?
It tends to be lower due to biosimilar competition and price reductions. However, it remains essential for cost-sensitive healthcare systems.

---

References

[1] MarketResearch.com, "Global Insulin Market Size & Forecast," 2023.
[2] EvaluatePharma, "Insulin Biosimilar Market Trends," 2022.
[3] FDA Official Website, "Biosimilar Insulin Approvals," 2023.
[4] IMS Health, "Diabetes Care Market Data," 2022.
[5] Statista, "Global Diabetes Prevalence," 2023.